SCHEMBL15217626

SCHEMBL15217626

CNc1ccc(O)c2ncccc12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 4/20 0.69
HTT P42858 3/20 0.61
SLC6A2 P23975 1/20 0.61
FTO Q9C0B1 1/20 0.60
MMP2 P08253 4/20 0.60
KDM4E B2RXH2 6/20 0.59
NPC1 O15118 2/20 0.58
GAA P10253 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
ALDH1A1 P00352 1/20 0.58
GFER P55789 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
HSP90AA1 P07900 2/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
LMNA P02545 2/20 0.56
MPI P34949 1/20 0.56
BRD4 O60885 1/20 0.56
MAPT P10636 1/20 0.56
METAP2 P50579 1/20 0.56
METAP1 P53582 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19799374 0.85 MEN1 (0.51) IDO1HTTMMP2NPC1TDP1
SCHEMBL24081122 0.84 IDO1 (0.66) IDO1HTTSLC6A2FTOMMP2
SCHEMBL14130573 0.82 IDO1 (0.64) IDO1HTTSLC6A2FTOMMP2
SCHEMBL22705016 0.82 IDO1 (0.64) IDO1HTTSLC6A2FTOMMP2
SCHEMBL28942142 0.82 IDO1 (0.64) IDO1HTTSLC6A2FTOMMP2
SCHEMBL12599076 0.81 IDO1 (1.00) IDO1HTTSLC6A2MMP2KDM4E
SCHEMBL12599074 0.81 IDO1 (1.00) IDO1HTTSLC6A2MMP2KDM4E
SCHEMBL7032474 0.80 IDO1 (0.61) IDO1HTTSLC6A2FTOMMP2
SCHEMBL14820067 0.80 HTR1A (0.53) IDO1HTTSLC6A2KDM4ENPC1
SCHEMBL22797153 0.79 GLO1 (0.49) IDO1MMP2KDM4ENPC1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression SIERRA SCIENCES, INC. (US) 2023-07-18 US disclosed
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression SIERRA SCIENCES, INC. (US) 2023-07-18 US disclosed
WO-2019056120-A1 PENTAFLUOROPHENYL SULFONAMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF DALRIADA THERAPEUTICS INC. (CA) 2019-03-28 WO disclosed
EP-2634178-B1 QUINAZOLINE DERIVATIVE AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICATION OF TUMOR CELLS AND PREPARATION METHOD THEREOF CHINESE ACAD INST CHEMISTRY (CN) 2016-08-24 EP disclosed
US-9233995-B2 Quinazoline derivatives and quinazoline complex protein kinase inhibitor for inhibiting multiplication of tumor cells and preparation method thereof INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) 2016-01-12 US disclosed
US-9233995-B2 Quinazoline derivatives and quinazoline complex protein kinase inhibitor for inhibiting multiplication of tumor cells and preparation method thereof INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) 2016-01-12 US disclosed
EP-2727916-A1 Neuroprotective multi-target directed drugs Universitat Autònoma de Barcelona (ES) 2014-05-07 EP disclosed
US-20130225811-A1 QUINAZOLINE DERIVATIVES AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICAITON OF TUMOR CELLS AND PREPARATION METHOD THEREOF INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCE (CN) 2013-08-29 US disclosed
US-20130225811-A1 QUINAZOLINE DERIVATIVES AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICAITON OF TUMOR CELLS AND PREPARATION METHOD THEREOF INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCE (CN) 2013-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression TERT, TERF2, RNGTT IDO1 4289/4885HTT 178/4885SLC6A2 2961/4885
US-20130225811-A1 QUINAZOLINE DERIVATIVES AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICAITON OF TUMOR CELLS AND PREPARATION METHOD THEREOF MAP3K21, MAP3K15, MAP3K14 IDO1 3552/4885HTT 4810/4885SLC6A2 4496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.